Patricia Van Arnum

Editorial Director, DCAT

[email protected]
Patricia Van Arnum is Editorial Director at the Drug, Chemical & Associated Technologies Association (DCAT), where she is responsible for delivering informational services for DCAT members. She is editor of DCAT Value Chain Insights, DCAT’s editorial newsletter providing news and analysis of the business of bio/pharmaceutical development and manufacturing covering the full spectrum of the bio/pharmaceutical manufacturing value chain. She also provides content advisement and support for DCAT’s volunteer committees. Overall, she has 30 years of experience covering the Bio/Pharmaceutical, Fine-Chemical and Chemical industries as a business and science editor. She is a member of the American Chemical Society, the American Association of Pharmaceutical Scientists, and the American Association for the Advancement of Science and holds undergraduate degrees in chemistry, economics, and political science.

LATEST

FDA Launches Pilot To Expedite INDs
By

By
FDA has launched a pilot program to expedite review of investigational new drug (IND) filings with applications for the pilot due by October 30. It is part of the agency’s Operation TrialBlazer initiative, designed to make the US more competitive in early-stage research.

Beyond ADCs: Next-Generation Drug Conjugates 
By

By
Antibody drug conjugates (ADCs) continue to be a strong growth area, but next-generation drug conjugates, encompassing oligonucleotides, peptides, and other small-molecule payloads, are on the rise.

Sandoz Maps Out Ambitious Biosimilars Growth Plan
By

By
Sandoz has rolled out a plan to increase its biosimilars portfolio to more than 100 biosimilars, including generic GLP-1’s by 2040, increase manufacturing capacity, and more than double its net sales by 2035.

US Government Moves To Counter Ex-US R&D
By

By
FDA announced plans to increase oversight of clinical trials overseas while proposing a pilot to shorten and remove barriers in the IND process as a means to increase US-based research and counter shifts to ex-US R&D.
Money-pills-flag

The Next Round in US Drug Pricing & Mfg Investments
By

By
The White House has signed nine new deals for most-favored-nation drug pricing with mid-sized pharma companies, bringing the total of such deals to 26 along with more committments for US-based manufacturing. 

Supply Planning: Are Foreign-Trade Zones the Right Tool?
By

By
Amid evolving trade policies, foreign-trade zones are a potential tool to support companies’ supply-chain strategies, but how can they be used?

Primary Packaging: The Moves and Capacity Additions
By

By
What have been the major moves—mergers and acquisitions and capacity additions in primary packaging? The latest developments and trends.

CDMOs/CMOs: The Key Moves in 2026
By

By
What have been the key moves—capacity additions and acquisitions by CDMOs thus far in 2026 and what may be on the horizon?

What’s Trending in Excipients
By

By
Excipients play a crucial role in formulation development, but what barriers to innovation in excipients exist and how is the industry addressing?

Pharma M&A: The Deals & the Molecules
By

By
What have been the key mergers and acquisitions by the large and mid-sized pharma companies thus far in 2026? DCAT Value Chain Insights evaluates the deal-making and the molecules involved.